Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
IPO Year: 1995
Exchange: NYSE
Website: waters.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $355.00 → $415.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $380.00 | Overweight | Wells Fargo |
| 8/1/2024 | $325.00 → $375.00 | Market Perform → Outperform | Leerink Partners |
| 6/3/2024 | $320.00 | Hold | Jefferies |
| 11/13/2023 | $270.00 → $230.00 | Equal Weight → Underweight | Barclays |
| 9/28/2023 | $280.00 | Mkt Perform | Bernstein |
| 7/31/2023 | $275.00 | Overweight → Equal Weight | Barclays |
| 7/31/2023 | $285.00 → $270.00 | Outperform → In-line | Evercore ISI |
| 12/14/2022 | $350.00 | Hold | Deutsche Bank |
| 8/25/2022 | $345.00 | Neutral | Credit Suisse |
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4/A - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
3 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
3 - WATERS CORP /DE/ (0001000697) (Issuer)
Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:WAT) with a In-Line and lowers the price target from $320 to $300.
Across the recent three months, 6 analysts have shared their insights on Waters (NYSE:WAT), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 3 1 0 3M Ago 0 0 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.67, a high estimate of $358.00, and a low estimate of $275.00. Experiencing a 0.1% decline,
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Underweight and lowers the price target from $295 to $275.
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Privia Health Group The Trade: Privia Health Group, Inc. (NASDAQ:PRVA) Director Adam Boehler acquired a total of 4,280 sha
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume GERN CALL TRADE BULLISH 09/20/24 $3.50 $350.0K 833 5.0K ZTS PUT SWEEP BULLISH 07/19/2
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Underweight and lowers the price target from $300 to $295.
TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Hold and raises the price target from $350 to $358.
Waters (NYSE:WAT) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 1 0 Last 30D 0 0 2 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 1 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $321.0, a high estimate of $340.00, and a low estimate of $300.00. Observing a 3.22% increase, the current average has risen from the p
Stifel analyst Daniel Arias maintains Waters (NYSE:WAT) with a Hold and raises the price target from $330 to $332.
Baird analyst Catherine Ramsey maintains Waters (NYSE:WAT) with a Neutral and lowers the price target from $319 to $312.
8-K/A - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
11-K - WATERS CORP /DE/ (0001000697) (Filer)
SD - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
MILFORD, Mass., Nov. 20, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4th, 2024 at 10:00AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations ser
News summary: Newly built 45,000 sq ft facility houses engineering and skilled manufacturing employees at Longbridge Business Park, a specialized hub for science and technology.Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth.New facility was constructed to BREEAM Very Good standard and achieved the highest Energy Performance Certificate rating.LONGBRIDGE, England, Nov. 13, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park in the West Midlands. The new facility more than triples existing operations and
News Summary: waters_connect™ Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development lifecycle, enabling real-time audit readiness and query response, while reducing time spent on audit preparation.Cloud-based software proactively provides visibility into risks that could trigger adverse regulatory findings, delivering seamless remote data access, comprehensive analytics, historical trends, scalability, and cost efficiency.Provides actionable insights from Waters™ Empower™ CDS software to help prevent system suitability failures, that can cost up to $600,000 per year.iMILFORD, Mass., Nov. 7, 2
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
News Summary: Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.Novel digestion enzymes deliver complete RNA sequence coveragei for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.iiNew waters_connect™ MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.MILFORD, Mass., Oct. 10, 2024 /PRNew
News Summary: Easy-to-use, compact analyzer makes rheological insights more accessible to quality testing laboratories and material production facilities in batteries, pharmaceuticals, food, consumer goods, and other industries.Powered by RheoGuide™ Software, a streamlined, modern touchscreen user interface with built-in self-guided methods, workflows, and training applications to simplify rheological testing for all users.Superior analytical performance at an affordable price, with up to 2x better torque sensitivityi of comparable rheometers on the market.DETROIT, Oct. 8, 2024 /PRNewswire/ -- The Battery Show -- Waters Corporation (NYSE:WAT) today introduced the TA Instruments™ Discovery Co
MILFORD, Mass., Oct. 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2024 financial results conference call live on Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 29th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. W
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
News Summary: Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x compared with competitor capillary DSC technologiesi.Streamlines thermal stability testing of biologics using disposable microfluidic chips (MFCs) enabling analysis under actual high-concentration drug dosing and use conditions.Delivers faster and more accurate measurements of high-concentration biological drug formulationsii with unique design that simplifies sample preparation and accelerates drug development.MILFORD, Mass., July 23, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced today the global release of the TA Instruments™ Rapid
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
Jefferies upgraded Waters from Hold to Buy and set a new price target of $415.00 from $355.00 previously
Wells Fargo initiated coverage of Waters with a rating of Overweight and set a new price target of $380.00
Leerink Partners upgraded Waters from Market Perform to Outperform and set a new price target of $375.00 from $325.00 previously
Jefferies resumed coverage of Waters with a rating of Hold and set a new price target of $320.00
Barclays downgraded Waters from Equal Weight to Underweight and set a new price target of $230.00 from $270.00 previously
Bernstein initiated coverage of Waters with a rating of Mkt Perform and set a new price target of $280.00
Barclays downgraded Waters from Overweight to Equal Weight and set a new price target of $275.00
Evercore ISI downgraded Waters from Outperform to In-line and set a new price target of $270.00 from $285.00 previously
Deutsche Bank initiated coverage of Waters with a rating of Hold and set a new price target of $350.00
Credit Suisse initiated coverage of Waters with a rating of Neutral and set a new price target of $345.00
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment
Dr. Michael J. Berendt to Retire from Waters Board Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM International, Inc., a leader in specialty coatings, sealants, building materials and related services. Waters also announced the retirement of Dr. Michael J. Berendt from its Board of Directors, effective October 5, 2021. Dr. Berendt joined the Waters Board in 1998 and has served on both the company's Audit and Science & Technology committees during his tenure as director. "Our sincere thanks and gratitude on behalf of my colleagues to Mike, for his serv
Waters Corporation (NYSE:WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China. Dr. Flemming Ornskov, Chairman of the Board, said, "We are excited to welcome Wei to the Board and know that we will benefit from his operating experience and transformation expertise. Wei has an outstanding record of driving results in regions that represent key growth opportunities for Waters, including China and other Asia-Pacific markets. We believe he is a valuable addition to the Board at this pivotal time f
MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021. “We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as a proven track record in drug discovery and the development of clinical trials. We look forward to benefitting from Pearl’s perspecti
MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Sherry Buck will step down as Chief Financial Officer, effective December 31, 2020, in order to pursue another opportunity at a privately held company. Upon her departure, Michael F. Silveira, Vice President and Corporate Controller of Waters, will assume the role of interim Chief Financial Officer. Ms. Buck will work alongside Mr. Silveira in order to facilitate a smooth transition. Waters has been actively working with a leading search firm to identify a permanent CFO, and the process is advancing well with several strong internal and external candidates. “On behalf of the Board and management,
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
MILFORD, Mass., Oct. 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2024 financial results conference call live on Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 29th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. W
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
MILFORD, Mass., July 2, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2024 financial results conference call live on Wednesday, July 31st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least August 28th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. Wit
Highlights Sales of $637 million at the high-end of guidance, declined 7% as reported and 9% in organic constant currencyGAAP EPS of $1.72; earnings well above guidance, with non-GAAP EPS of $2.21Operational excellence drove gross margin expansion of 40 basis points and adjusted operating margin expansion of 20 basis pointsStrong operating cash flow generation at $263 million; free cash flow of $234 million was 37% of sales Full-year guidance maintained at -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05First Quarter 2024 MILFORD, Mass., May 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first qua
MILFORD, Mass., April 11, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 4th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With app
Highlights Fourth Quarter 2023 Sales of $819 million declined 4.5% as reported and 8% in organic constant currency, in line with guidanceOperational excellence drove gross margin expansion of 170 basis points and adjusted operating margin expansion of 120 basis pointsNon-GAAP EPS of $3.62 at the high end of guidance; GAAP EPS of $3.65Full-Year 2023 Strong execution in tough market conditions delivered sales of $2,956 million, a decline of 0.5% as reported and 2% in organic constant currency, as expectedWyatt acquisition delivered an on-target M&A contribution of 2.5% to salesGross margin expanded 160 basis points to 59.6% and adjusted operating margin expanded 70 basis points to 30.9%MILFORD
MILFORD, Mass., Jan. 18, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2023 financial results conference call live on Tuesday, February 6th, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 5th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. Wi
MILFORD, Mass., Oct. 10, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2023 financial results conference call live on Tuesday, November 7th, 2023 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 21, 2023, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With approximately
Highlights Sales of $741 million grew 4% as reported and 3% in organic constant currencyStrength led by double-digit growth in Industrial and Academic & GovernmentOperational excellence added 230 basis points of gross margin expansionHigh single-digit organic constant currency growth in the U.S. and Europe was partially offset by Pharma weakness in ChinaWyatt acquisition ahead of expectations with 2% sales contribution in the quarterMILFORD, Mass., Aug. 2, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial results for the second quarter of 2023. Sales for the second quarter of 2023 were $741 million, an increase of 4% as reported, compared to sales of $714 milli